Downregulation of Survivin by Adenovirus-mediated ShRNA Promotes Apoptosis in Skin Cancer Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 May 24

PMID 31118663

Citations 1

Authors

Yuqin Hao

XueFeng Bai

Xia Liu

Shuxia Kang

Xin Zhang

Caiyun Liu

Zhehai Li

Affiliations

Soon will be listed here.

Abstract

Background: Survivin, a member of the inhibitor of apoptosis protein family, is highly expressed in many cancers and has important roles in inhibiting apoptosis by blocking caspase activation. However, its antitumor effects remain largely unknown. Here we explore the function of survivin in skin cancer.

Methods: We used qPCR and Western blot to examine survivin expression in skin cancer patients and cell line. We generated several survivin shRNA constructs and tested the effects of survivin shRNA on cancer cell viability using MTT assay, flow cytometry, and TUNEL assay.

Results: We found that survivin was upregulated in both skin cancer patients and skin cancer cell line A431. Knockdown survivin via shRNA inhibited cancer cell proliferation and promoted apoptosis in both A431 cell and in vivo xenograft tumor mouse model. The antitumor effect is comparable to resveratrol, a drug known to inhibit cancer progression. Moreover, we showed that inhibition of survivin was able to increase the expression of cleaved caspase 7/caspase 9 and activate the ataxia-telangiectasia mutated-NF-κB pathway in A431 cells.

Conclusion: Survivin-shRNA possesses antitumor abilities in vitro and in vivo by inhibiting the proliferation and promoting apoptosis of A431 cells. It may serve as a potential anticancer target for skin cancer therapy in the future.

Citing Articles

Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA.

Ke J, Zhang J, Li J, Liu J, Guan S Int J Mol Sci. 2022; 23(20).

PMID: 36292932 PMC: 9602810. DOI: 10.3390/ijms232012071.

References

Aggarwal B, Bhardwaj A, Aggarwal R, Seeram N, Shishodia S, Takada Y . Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004; 24(5A):2783-840. View

Lee J, Chang K, Han J, Ryu H . Survivin, a novel anti-apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors. Int J Gynecol Cancer. 2005; 15(1):113-9. DOI: 10.1111/j.1048-891X.2005.15011.x. View

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

Wang K, Brems J, Gamelli R, Holterman A . Survivin signaling is regulated through nuclear factor-kappa B pathway during glycochenodeoxycholate-induced hepatocyte apoptosis. Biochim Biophys Acta. 2010; 1803(12):1368-75. DOI: 10.1016/j.bbamcr.2010.08.008. View

Cheung C, Cheng L, Chang K, Chen H, Chang J . Investigations of survivin: the past, present and future. Front Biosci (Landmark Ed). 2011; 16(3):952-61. DOI: 10.2741/3728. View

Bongiovanni L, Muller E, Della Salda L . Survivin in skin pathologies. Exp Dermatol. 2011; 20(6):457-63. DOI: 10.1111/j.1600-0625.2011.01273.x. View

Aluyen J, Ton Q, Tran T, Yang A, Gottlieb H, Bellanger R . Resveratrol: potential as anticancer agent. J Diet Suppl. 2012; 9(1):45-56. DOI: 10.3109/19390211.2011.650842. View

Carter L, DOrazio J, Pearson K . Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014; 21(3):R209-25. PMC: 4013237. DOI: 10.1530/ERC-13-0171. View

Zhang Y, Huang H, Zhou H, Du T, Zeng L, Cao Y . Activation of nuclear factor κB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer. Cancer. 2014; 120(20):3208-18. DOI: 10.1002/cncr.28796. View

10.

D L Brougham N, Tan S . The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma--implications on the T-classification system. J Surg Oncol. 2014; 110(7):876-82. DOI: 10.1002/jso.23731. View

11.

Parikh S, Patel V, Ratner D . Advances in the management of cutaneous squamous cell carcinoma. F1000Prime Rep. 2014; 6:70. PMC: 4126542. DOI: 10.12703/P6-70. View

12.

Singh C, Ndiaye M, Ahmad N . Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta. 2014; 1852(6):1178-85. PMC: 4380791. DOI: 10.1016/j.bbadis.2014.11.004. View

13.

Lee J, Oh E, Yoo J, Choi K, Yoon M, Yun C . Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget. 2015; 6(6):4051-65. PMC: 4414172. DOI: 10.18632/oncotarget.3018. View

14.

Liu H, Wang Y, Wang L, Hao M . P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Exp Mol Pathol. 2015; 99(1):44-9. DOI: 10.1016/j.yexmp.2015.04.004. View

15.

Yu X, Li Z . The role of miRNAs in cutaneous squamous cell carcinoma. J Cell Mol Med. 2015; 20(1):3-9. PMC: 4717857. DOI: 10.1111/jcmm.12649. View

16.

Li Y, Wang X, Zhang L, Lv X, Su X, Tian S . A SNP in pri-miR-10a is associated with recurrent spontaneous abortion in a Han-Chinese population. Oncotarget. 2016; 7(7):8208-22. PMC: 4884987. DOI: 10.18632/oncotarget.7002. View

17.

Yu H, Xiong J, Zhang R, Hu X, Qiu J, Zhang D . Ndk, a novel host-responsive regulator, negatively regulates bacterial virulence through quorum sensing in Pseudomonas aeruginosa. Sci Rep. 2016; 6:28684. PMC: 4921839. DOI: 10.1038/srep28684. View

18.

Burton K, Ashack K, Khachemoune A . Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol. 2016; 17(5):491-508. DOI: 10.1007/s40257-016-0207-3. View

19.

Philchenkov A, Miura K . The IAP Protein Family, SMAC Mimetics and Cancer Treatment. Crit Rev Oncog. 2016; 21(3-4):185-202. DOI: 10.1615/CritRevOncog.2016017032. View

20.

Selvam C, Mutisya D, Prakash S, Ranganna K, Thilagavathi R . Therapeutic potential of chemically modified siRNA: Recent trends. Chem Biol Drug Des. 2017; 90(5):665-678. PMC: 5935465. DOI: 10.1111/cbdd.12993. View